TransThera Sciences (Nanjing), Inc. (HKG:2617)

HKG:2617 Ratios and Metrics

Market cap in millions HKD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022
Period Ending	Mar 5, 2026	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Debt / Equity Ratio	0.01	0.01	0.01	0.00
Net Debt / Equity Ratio	-1.09	-1.08	-1.06	-0.90
Net Debt / EBITDA Ratio	2.59	1.97	2.20	3.21
Net Debt / FCF Ratio	2.47	2.09	2.58	4.11
Asset Turnover	-	-	0.00	-
Quick Ratio	5.79	5.56	8.18	10.15
Current Ratio	5.89	5.66	8.24	11.98
Return on Equity (ROE)	-39.08%	-41.98%	-36.63%	-
Return on Assets (ROA)	-21.10%	-24.05%	-23.02%	-
Return on Capital Employed (ROCE)	-42.40%	-55.40%	-48.80%	-28.60%
Buyback Yield / Dilution	-0.08%	-0.06%	-5.83%	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.